Assiut University Hospital
Asyut, Assiut Governorate, Egypt
Location contact
Amna A Taher, Resident
CONTACT
Amna A Taher, Resident
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07455799
the effect of missed hemodialysis sessions on the occurrence of short-term cardiovascular events in patients with end-stage renal disease receiving maintenance hemodialysis.
Trial opening soon.
Get Notified18 year–85 year
All sexes
Observational
Asyut, Assiut Governorate, Egypt
Amna A Taher, Resident
CONTACT
Amna A Taher, Resident
PRINCIPAL_INVESTIGATOR
End-stage renal disease (ESRD) represents a major and growing global health burden, with a steadily increasing prevalence worldwide. Patients receiving maintenance hemodialysis (HD) experience markedly elevated rates of cardiovascular morbidity and mortality compared with the general population (1).
Cardiovascular disease accounts for nearly half of all deaths among HD patients, reflecting the combined effects of traditional cardiovascular risk factors and dialysis-specific stressors, including large volume shifts, electrolyte disturbances, chronic inflammation, and autonomic dysfunction (2).
Maintenance HD is designed to preserve physiological homeostasis through regular removal of excess fluid, electrolytes, and uremic toxins. Adherence to the prescribed dialysis schedule is therefore essential for maintaining cardiovascular stability (3).
Despite its life-sustaining role, HD is an inherently complex and time-consuming therapy, typically delivered three times weekly for several hours per session. This demanding regimen imposes substantial physical, psychological, and socioeconomic burdens on patients and contributes to persistently high rates of hospitalization and mortality (4).
Missed HD sessions or delays in treatment represent a common and clinically significant challenge in routine dialysis care, with observational studies indicating that 515% of patients miss at least one scheduled session annually. Disruption of the regular dialysis schedule results in prolonged interdialytic intervals and loss of metabolic and volume control (5).
Importantly, missed treatments are not solely attributable to patient nonadherence. A wide range of contributing factors has been identified, including logistical barriers such as unreliable transportation, long travel times to dialysis units, adverse weather conditions, and scheduling of sessions on weekends or holidays. Medical factors such as gastrointestinal symptoms, vascular access dysfunction, chronic pain, depression, and substance use further contribute to treatment nonattendance. Additionally, demographic and psychosocial factors, including older age, limited health literacy, race or ethnicity, and lack of social or marital support, play an important role (6).
The consequences of missed HD sessions extend beyond inadequate solute clearance. Prolonged interdialytic intervals lead to acute physiological derangements, including progressive fluid overload, worsening hypertension, hyperkalemia, metabolic acidosis, and accumulation of uremic toxins. These abnormalities impose significant myocardial stress and increase electrical instability (7).
The cardiovascular system of HD patients is particularly vulnerable to abrupt changes in preload and afterload. Excess interdialytic weight gain following missed sessions increases cardiac workload and predisposes patients to acute heart failure decompensation. Concurrently, electrolyte disturbances particularly hyperkalemia may precipitate malignant arrhythmias, while autonomic imbalance and heightened sympathetic activity further amplify the risk of sudden cardiac events (8).
Consistent with these pathophysiological mechanisms, studies comparing scheduled dialysis days have demonstrated higher rates of cardiovascular events following longer interdialytic gaps. Moreover, skipped treatments have been associated with sharply increased short-term risks of hospitalization and mortality, particularly within 4872 hours the missed session (9).
Additionally, Missed HD sessions have also been linked to unfavorable anemia-related outcomes, including lower hemoglobin levels and increased requirements for erythropoiesafteris-stimulating agents, further reflecting compromised dialysis adequacy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A standard 12-lead ECG will be performed for all patients within 72 hours after a missed hemodialysis session to detect abnormalities.Transthoracic echocardiography will be performed as a baseline assessment for all enrolled patients using routine institutional protocols. Repeat echocardiographic examination will be performed only if clinically indicated,Echocardiographic parameters assessed will include left ventricular ejection fraction , left ventricular hypertrophy, regional wall motion abnormalities, diastolic function, and right ventricular function
Time frame: 1 year
Short-term cardiovascular events will be defined as the occurrence of acute coronary syndrome, acute decompensated heart failure, documented arrhythmias, sudden cardiac death, or cerebrovascular events occurring within 72 hours after a missed hemodialysis session.
Contact information is provided by the study sponsor or research team.
Assiut University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07649083
Arteriovenous Fistula, Arteriovenous Malformations
View Trial DetailsNCT07575607
Chronic Disease, Disease Attributes
Zagazig, Sharqia Governorate, Egypt
View Trial DetailsNCT07548151
Cannulation, Chronic Disease
Tashkent, Uzbekistan
View Trial DetailsNCT07129083
Chronic Disease, Disease Attributes
Ghent, Oost-Vlaanderen, Belgium
View Trial Details